MB-40: THE 15 YEARS CLINICAL EXPERIENCE OF MULTIDISCIPLINARY TREATMENT FOR MEDULLOBLASTOMA IN CHILDREN: ANALYSIS OF 122 CASES

BACKGROUND: Medulloblastoma is a primary pediatric brain tumors that requires multidisciplinary therapies. We summarized and reported the management and the therapeutic efficacies of medulloblastomas in our cancer center. METHODS: We evaluated 122 pts newly diagnosed as medulloblastoma from Feb 2000 to Dec 2015 retrospectively. Mean patient age was 9 years (range, 16months to 21 years), including 95.1% (116/122) pts who were ≥ 3years old. There were 68.8% (84/122) with brainstem compression, 67.2% (82/122) with moderate and severe hydrocephalus, 4.9%(6/122) spinal dissemination. After gross total resection, pts ≥ 3years old underwent craniospinal radiation 24 Gy with boosting primary brain site to 56Gy, followed by 6 cycles of chemotherapies including VCR,CCNU and DDP; pts < 3 years old only underwent alternated chemotherapy including IFO, VP16,CTX, VCR etc. RESULTS: At a median follow-up of 7.3 years, the 2-year OS and 5-year OS were 71.3% and 25.5%, respectively. 5-year OS of heightened risk and average risk were 17.6% and 73.1% respectively. There were 30 cases who died from tumor relapsed with 28 cases of primary site relapse and 4 of spinal dissemination. And there was no significant relationship between the brainstem compression and the prognosis. CONCLUSION: Combination of radiation and chemotherapy following gross total resection is an effective and tolerable treatment for pediatric medulloblastoma. The prognosis is much poorer in heightened risk pts. Searching the tumor markers combined with molecular diagnostics mode may improve the survival of pediatric medulloblastoma.